MCRB: Seres Therapeutics Inc. Company Value to Net Income

Corporate emblem and logo of Seres Therapeutics Inc. (MCRB)

Seres Therapeutics possesses significant market influence thanks to Vowst, the first FDA-approved treatment for restoring the gut microbiome. The company's price evolution demonstrates the -0.30 metric, while the business scales global patents for high-margin innovative capsules. Operations conclude with strict adherence to environmental standards regarding biomaterial disposal and effluent control.

Seres Therapeutics Inc. (MCRB) Price to Earnings Ratio: for the period 07/04/2022 - 11/17/2026

Comprehensive metric breakdowns and analytics for Seres Therapeutics Inc. (MCRB)

- price and consensus price forecast:
Summary company analysis:MCRB Seres
Manufactured products of Seres Therapeutics, Inc.

Stable supplies of biomass for Seres Therapeutics (MCRB) allow for a real-time assessment of the business's intrinsic value via the company's P/E ratio on GURU.Markets. This ratio reflects the relationship between market capitalization and net income, determining the investment payback period. The indicator is calculated by dividing the share price by earnings per share, identifying whether the asset is overvalued. Optimization of warehouse reserves in the US minimizes operational risks, ensuring capital stability.